As you know, there is no cure, yet. There are many studies going on and the results are very
    promising. They are getting closing to better understand the disease and thus design a cure.

    There are six drugs approved for the treatment of the relapsing-remitting forms of MS.

    Avonex®, Betaseron®, Copaxone®, Rebif® and Tysabri® are considered disease-modulating
    drugs. They help control the symptoms and some of them have recently shown certain positive
    effect that results in a slow repair of the affected nerve. The one to use depends on your doctor's
    decision on what could work better for you.

    Avonex® (interferon beta 1-a) manufactured by Biogen Idec, is administer by intramuscular
    injection once a week. It has shown to reduce the severity and frequency of MS attacks and reduce
    the lesions (active or new) in the brain.

    Betaseron® (interferon beta 1-b) manufactured by Berlex Laboratories, Inc., Extavia® (Interferón beta
    1-b) manufactured by Novartis, Incis administer by subcutaneous (underneath the skin) injection every
    other day. It has shown to reduce the severity and frequency of MS attacks and reduce the lesions
    (active or new) in the brain.

    Copaxone® (glatiramer acetate) manufactured by TEVA Neuroscience, Inc., is administer every day
    by subcutaneous injection. It has shown to reduce the frequency of MS attacks and reduce the
    lesions (active or new) in the brain.

    Rebif® (interferon beta 1-a) manufactured by Serono, Inc., is administer three times a week by
    subcutaneous injection. It has shown to reduce the frequency of MS attacks and reduce the lesions
    (active or new) in the brain and may slow progression of disability.

    Tysabri® (natalizumab) manufactured by Biogen Idec and Elan Pharmaceuticals, by iv infusion every
    four weeks. Tysabri is generally recommended for patients who have had inadequate response to,
    or are unable to tolerate, other approved MS therapies. It is approved as a monotherapy, not to be
    combined with other immune system-modifying agents, and is not recommended for individuals who
    have weakened immune systems. It was first withdrawn after three patients developed a serious
    viral infection of the brain. It is approved to be use with a special restricted distribution program
    See questions and answers on Tysabri from NMSS website:
    http://www.nationalmssociety.org

    Novantrone® (mitoxantrone) manufactured by Serono, Inc., is administered four times a year by IV
    infusion in a medical facility. It is powerful immune system suppressor approved to be used in
    worsening relapsing-remitting ms as well as secondary progressive MS and all progressive forms of
    the MS. It has shown to reduce the frequency of MS attacks and reduce the lesions (active or new)
    in the brain and may slow progression of disability.

    Besides the disease-modifying drugs, there are other therapies available for specific symptoms like
    fatigue, pain, depression, spasticity, occupational therapy (for work) and cognitive therapy (for
    memory problems) among others. You should talk to your doctor to coordinate the therapy that is
    appropriate for you.

    See  Latest News



Disclaimer
WE WILL NOT BE LIABLE TO YOU OR ANY THIRD PARTY FOR ANY DIFFICULTY IN USE, INACCURACY OR
INCOMPLETENESS OF INFORMATION, USE OF THIS INFORMATION OR RESULTS ARISING FORM THE USE
OF IT, COMPUTER VIRUSES, MALICIOUS CODE, LOSS OF DATA, COMPATIBILITY ISSUES, OR
OTHERWISE. WE WILL NOT BE LIABLE TO YOU OR ANY THIRD PARTY FOR ANY DIRECT, INDIRECT,
SPECIAL INCIDENTAL, CONSEQUENTIAL, EXEMPLARY OR PUNITIVE DAMAGES (INCLUDING LOST
PROFITS, LOST DATA. COST TO PROCURE REPLACEMENT SERVICES OR GOODS, OR BUSINESS
OPPORTUNITIES) ARISING OUT OF YOUR ACCESS TO OR USE OF OUR SITE, OR ANY OTHER LINK WE
PROVIDE TO ANOTHER SITE, OR ANY ACTS, OMISSIONS, DEFECTS, SECURITY BREACHES, OR DELAYS,
REGARDLESS OF THE BASIS OF THE CLAIM OR IF WE HAVE BEEN ADVISED OF THE POSSIBILITY OF
SUCH DAMAGE OR LOSS. EACH PERSON IS RESPONSIBLE TO CONSULT THE INFORMATION WITH THEIR
PHYSICIAN.







Maria A Reyes-Velarde,
MD, MPH
hablemosdeem.com
Treatment
Permission to use/copy any part of the site
"HABLEMOS DE ESCLEROSIS MULTIPLE" must
be granted by the author
ESCLEROSIS  MULTIPLE
©2001-2012maria a. reyes-velarde